About Migraine

Migraine is under-recognized and undertreated1,2

More than 30 million adults suffer with migraine in the US2-4

In the American Migraine Prevalence and Prevention (AMPP) study, which surveyed households to identify people with migraine1:

~50% of people with migraine had received a migraine diagnosis image

Preventive treatment is underutilized in migraine2

According to the AMPP study2:

35% Migraine Candidates image
10% Migraine Preventive Users image

Migraine can have a profound impact on people’s lives2,5

Migraine can lead to reduced productivity and cost people valuable time for work, household tasks, and leisure2,5

Presentation Board Icon

Migraine may affect a person’s productivity at work2

  • Nearly 30% of people with migraine reported that their productivity at work was reduced by at least 50% in the previous 3 months in the AMPP study
House Icon

Migraine may affect a person’s productivity at home2,5

  • 85% of people reported substantial reductions in their ability to do household work or chores due to migraine in a survey of 389 people with migraine living with a household partner as reported in the family impact of migraine study
  • More than one-third of people with migraine reported that household productivity was reduced by at least 50% in the previous 3 months in the AMPP study
Calendar Icon

Migraine may cause a person to miss leisure time and activities5

  • 45% of people reported missing family, social, and leisure activities due to migraine in a survey of 389 people with migraine living with a household partner as reported in the family impact of migraine study

Consider migraine prevention for patients like Jessicaa

Clinical profile

Age: 38

Migraine frequency: 4-14 migraine headache days (MHDs) per month

Treatment history:

  • Has implemented lifestyle modifications
  • Has tried various acute treatment options
  • May have tried preventives

aNot an actual patient.

Jessica Profile Image

Assess the impact of migraine to inform your treatment plan

An impact assessment helps you uncover the burden migraine is placing on your patients’ lives. This understanding can assist you in recommending a treatment plan that may be right for your patients.

Download this tool to help facilitate a discussion with your patient about migraine.

CGRP is thought to play a central role in migraine pathogenesis6

Elevated levels of calcitonin gene-related peptide (CGRP) can lead to a cascade of vasodilation and pain associated with migraine attacks, as observed in preclinical studies of CGRP6

  • CGRP, released from the trigeminal ganglia, is elevated during migraine6
  • An infusion of CGRP can induce migraine attacks in susceptible individuals, and CGRP is involved in the transmission of pain7,8
  • Perivascular release of CGRP has been shown to induce vasodilation and plasma protein leakage from tissues6
Emgality CGRP Receptor image

References: 1. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355-363. 2. Lipton RB, Bigal ME, Diamond M, et al; for the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0028. 4. US Census Bureau. Quick facts. https://www.census.gov/quickfacts/fact/table/US/PST045217. Accessed January 12, 2019. 5. Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23:429-440. 6. Durham PL. CGRP-receptor antagonists—A fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073-1075. 7. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54-61. 8.Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987;403:350-354.

Indication and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.